104750-60-9

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-1-(METHOXYMETHOXY)-4-METHYLBENZENE is used as a building block for the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 2-BROMO-1-(METHOXYMETHOXY)-4-METHYLBENZENE serves as an intermediate in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Organic Chemistry Research:
As a research chemical, 2-BROMO-1-(METHOXYMETHOXY)-4-METHYLBENZENE is utilized in organic chemistry laboratories for studying its properties and exploring its potential applications in various chemical reactions and synthesis processes.

Upstream product

• 25458-49-5 1-(methoxymethoxy)-4-methylbenzene 
• 6627-55-0 2-bromo-p-cresol 
• 107-30-2 chloromethyl methyl ether 
• 109-87-5 Dimethoxymethane 
• 13057-17-5 bromethyl methyl ether 

Downstream Products

• 104750-62-1 3-(2-Methoxymethoxy-5-methyl-phenyl)-propionic acid ethyl ester 
• 162269-58-1 2-(2-hydroxy-5-methylbenzoyl)-3-hydroxypyridine 
• 70978-57-3 2,2,2-trifluoromethyl-1-(2-hydroxy-5-methylphenyl)ethan-1-one 
• 1202677-30-2 4-methyl-2-(pyridin-4-yl)phenol 
• 36808-15-8 2-(methoxymethoxy)-5-methylphenol 
• 1435949-49-7 4-(2-hydroxy-5-methylphenoxy)-3-methoxybenzoic acid 
• 1436378-73-2 4-(2-hydroxy-5-methylphenoxy)-N-[(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl}-2-methylpropyl]-3-methoxybenzamide 
• 1435949-53-3 2-[2-(methoxymethoxy)-5-methylphenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1370521-32-6 (Z)-2-[3-ethoxy-1-(4-methoxyphenyl)prop-1-en-1-yl]-1-(methoxymethoxy)-4-methylbenzene 
• 869336-04-9 C₂₃H₂₀O₂ 
• 854779-53-6 6-{[[1-(2-methoxymethoxy-5-methyl-phenyl)-1H-imidazol-4-ylmethyl]-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-nicotinic acid methyl ester 
• 675583-74-1 6-{[[1-(2-methoxymethoxy-5-methyl-phenyl)-1H-imidazol-4-ylmethyl]-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-nicotinic acid 

Relevant academic research and scientific papers

Polymerizations for olefin-based polymers

The invention provides a process to form an olefin-based polymer, said process comprising polymerizing at least one olefin in the presence of at least one catalyst system comprising the reaction product of the following: A) at least one cocatalyst; and B) a procatalyst comprising a metal-ligand complex of Formula (I), as described herein:

A study of enantioselective syntheses by Sharpless asymmetric oxidation for aryl sulfoxides containing oxygen groups at the ortho position

Abstract: While ortho-alkoxy aryl sulfoxides including various substituents were synthesized by Sharpless asymmetric oxidation reaction, we optimized the reaction conditions and screened better combination of starting materials to obtain high enantioselectivity. The result suggested new information that electron-withdrawing substituents on the aromatic ring have a strong influence upon enantioselectivity of the products. Also, several chiral ligands for Sharpless asymmetric oxidation reaction were evaluated to improve the enantioselectivity. Graphic abstract: High enantioselectivity of ortho-alkoxy aryl chiral sulfoxides have been achieved by Sharpless oxidation reaction using Ti(O-i-Pr)4 and diethyl tartrate under anhydrous condition. In particular, the enantioselctivity of products was influenced by electron-withdrawing substituents on the aromatic ring, such as nitro, ester and aldehyde groups.[Figure not available: see fulltext.]

Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use

The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Synthesis of indole-fused heteroacenes by cascade cyclisation involving rhodium(ii)-catalysed intramolecular C-H amination

Heteroacenes are potentially important materials for organic electronics and their syntheses are of topical interest. Herein we report the development of a catalytic, redox-neutral reaction for the synthesis of the 5,10-dihydroindolo[3,2-b]indole class of

Rhodium(II)-Catalyzed Aryl C?H Carboxylation of 2-Pyridylphenols with CO2

A protocol for C?H carboxylation of electron-deficient 2-pyridylphenols with CO2 through a Rh(II)-catalyzed C?H bond activation under redox-neutral conditions has been developed. A suitable phosphine ligand was crucial for this reaction. This m

CATALYST SYSTEMS FOR OLEFIN POLYMERIZATION

The instant invention provides a procatalyst comprising a metal-ligand complex of Formula (I): (Formula I), wherein M, X, n, each Z, L, R21, R22 and R1 through R20 are each described herein.

Highly Enantioselective Construction of Fluoroalkylated Quaternary Stereocenters via Organocatalytic Dehydrated Mannich Reaction of Unprotected Hemiaminals with Ketones

A general organocatalytic asymmetric dehydrated Mannich reaction of fluoroalkyl hemiaminals with ketones is reported. In this Mannich reaction, previously less explored aryl ketones showed great reactivity. By virtue of this efficient method, a wide range of biologically active β-amino ketones were directly obtained. More importantly, two different intermediates involved in the reaction were detected and identified by 19F NMR and HRMS analysis. Furthermore, the synthetic utility of the products was demonstrated by the synthesis of the biologically active fluoroalkyl β-amino alcohols.

Synthetic models of the active site of cytochrome c oxidase: Influence of tridentate or tetradentate copper chelates bearing a his-tyr linkage mimic on dioxygen adduct formation by heme/cu complexes

Two synthetic models of the active site of cytochrome c oxidase-[(L N4-OH)CuI-FeII(TMP)]+ (1a) and [(LN3-OH)CuI-FeII(TMP)]+ (2a)-have been designed and synthesized. These models

BRIDGED BI-AROMATIC CATALYSTS, COMPLEXES, AND METHOD OF USING THE SAME

Ligands, compositions, metal-ligand complexes and arrays with substituted bridged bis-biaromatic ligands and method of making and using the same, are disclosed that are useful in the catalysis of transformations such as the polymerization of monomers into

Synthesis and biological activity of novel 2-(α- alkoxyimino)benzylpyridine derivatives as K+ channel openers

The search for novel K+ channel openers with a non-benzopyran skeleton, unlike cromakalim, led to the discovery of a new series of (Z)-2-(α- alkoxyimino)benzylpyridine derivatives. Synthesis was achieved by using a (Z)-dominant condensation reaction of henzoylpyridines with O- alkylhydroxylamines, followed by m-chloroperhenzoic acid (m-CPBA) oxidation. The compounds were tested for their vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2- and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for their effects on the coronary blood flow (CBF) after intracoronary injection in anesthetized dogs. A large number of the 2-(α- alkoxyimino)benzylpyridines strongly inhibited TEA and BaCl2-induced contraction, had no effect on 80 mM KCl-induced contraction, and increased the CBF to more than 200% of the basal flow at 10-30μg/dog. In particular, (Z)-2-[5-bromo-α-(tert-butoxyimino)-4-fluoro-2-hydroxybenzyl]-3- hydroxypyridine 1-oxide (7d) showed highly potent vasorelaxant activity (EC50=0.28μM) comparable to that of levcromakalim (EC50=0.17 μM), and gave a significantly longer-lasting increase (T ( 1/4 ) = 30 min) in the CBF compared to levcromakalim, nicorandil, nitroglycerin, or diltiazem (T( 1/4 )=5.2, 0.9, 0.4, and 2.2 min, respectively). It also exhibited a stable and long-lasting hypotensive effect (over 7h) upon oral administration of 1 mg/kg in spontaneously hypertensive rats (SHRs).